⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207506 | 0.71 | KDM4E (0.37) | — | |
| SCHEMBL22881711 | 0.68 | CHEK1 (0.41) | — | |
| SCHEMBL207610 | 0.65 | — | — | |
| SCHEMBL5891783 | 0.64 | — | — | |
| SCHEMBL13833538 | 0.63 | KDM4E (0.32) | — | |
| SCHEMBL9550046 | 0.62 | KDM4E (0.31) | — | |
| Hydrochloric Acid SCHEMBL18281396 | 0.61 | KDM4E (0.34) | — | |
| SCHEMBL2320427 | 0.61 | — | — | |
| SCHEMBL2115713 | 0.60 | — | — | |
| SCHEMBL17781247 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025136898-A1 | AGONISTS OF TREM2 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| US-9273054-B2 | Substituted pyrimido[1,6-a]pyrimidines as Lp-PLA2 inhibitors | GLAXO GROUP LIMITED (GB) | 2016-03-01 | — | — | US | disclosed |
| EP-2121687-B1 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-10-14 | — | — | EP | disclosed |
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-8513276-B2 | Imidazo[1,2-a]pyridine compounds for use in treating cancer | ASTEX THERAPEUTICS LIMITED (GB) | 2013-08-20 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100093718-A1 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2121687-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008078100-A2 | TRICYCLIC AMINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |